834869-04-4

Basic information

• Product Name: 7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile
• Synonyms: 7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile;IMidazo[1,2-a]pyridine-8-carbonitrile, 7-Methoxy-
• CAS NO: 834869-04-4
• Molecular Formula: C9H7N3O
• Molecular Weight: 173.17
• Product Categories: blocks;Carboxes;Pyridines
• Mol File: 834869-04-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.96±0.50(Predicted)
• CAS DataBase Reference: 7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile(834869-04-4)
• EPA Substance Registry System: 7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile(834869-04-4)

Safety Data

• Hazardous Substances Data: 834869-04-4(Hazardous Substances Data)

Usage

General Description

7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile, also known as 7-Methoxyimidazopyridine-8-carbonitrile or 7-Methoxy-1H-imidazo[1,2-a]pyridine-8-carbonitrile, is a chemical compound with the molecular formula C10H7N4O. It is a heterocyclic compound that contains both nitrogen and oxygen atoms in its structure. This chemical is mainly used as a building block for the synthesis of various pharmaceutical and agrochemical products. It has potential applications in the development of new drugs and as a tool in chemical research due to its unique structure and properties. Additionally, it is a valuable intermediate in organic synthesis and is used for the preparation of other complex organic compounds.

Upstream product

• 107-20-0 2-chloroethanal 
• 98651-70-8 2-amino-4-methoxypyridine-3-carbonitrile 

Relevant articles and documents

IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.